Ependymoma Pipeline Review, H2 2018: Therapeutic Development & Assessment, Companies, Drug Profiles & Dormant Projects – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ependymoma
– Pipeline Review, H2 2018”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Ependymoma – Pipeline Review, H2 2018, provides comprehensive
information on the therapeutics under development for Ependymoma
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Ependymoma (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Ependymoma and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase II, Phase I and Preclinical stages are
9, 2 and 1 respectively. Similarly, the Universities portfolio in
Preclinical stages comprises 2 molecules, respectively.

Ependymoma (Oncology) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Ependymoma – Overview
  3. Ependymoma – Therapeutics Development
  4. Ependymoma – Therapeutics Assessment
  5. Ependymoma – Companies Involved in Therapeutics Development
  6. Ependymoma – Drug Profiles
  7. Ependymoma – Dormant Projects
  8. Appendix

Companies Mentioned

  • Advantagene Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Eli Lilly and Co
  • Kite Pharma Inc
  • NewLink Genetics Corp
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4hnpvh/ependymoma?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs
, Brain
Cancer Drugs

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.